Company BioNexus Gene Lab Corp.

Equities

BGLC

US0906282076

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:05:11 2024-05-15 pm EDT			5-day change	1st Jan Change
0.591 ^USD	+1.39%		-1.69%	+9.43%

Apr. 16	BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 29	BioNexus Gene Lab Corp. Provides Information to Shareholders	CI

BioNexus Gene Lab Corp., through its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., focuses on the wholesale of chemical raw material products. The Company is engaged in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. The Company is also engaged in the business of developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. It offers a range of fiberglass reinforced plastic (FRP) products, which include Polyester Resin SHCP 268, Polyester Resin 9509 and Polyester Resin 2802. The FRP and other raw materials it offers are used to produce a variety of goods, including handrails, bench tops, cleanroom panels, and covers for various instruments used in manufacturing.

Number of employees: 30

USD in Million	2022	Weight	2023	Weight	Delta
Chemrex 99.8 %	11	99.1 %	10	99.8 %	-10.03%
MRNA Scientific Malaysia 0.2 %	0	0.9 %	0	0.2 %	-74.72%

USD in Million	2022	Weight	2023	Weight	Delta
Malaysia 100.0 %	11	100.0 %	10	100.0 %	-10.60%

Managers	Title	Age	Since
Lee Su-Leng Tan CEO	Chief Executive Officer	40	23-07-31

Members of the board	Title	Age	Since
Chee Keong Yap BRD	Director/Board Member	68	22-03-06
Wei Foong Lim BRD	Director/Board Member	48	Dec. 10
Lee Su-Leng Tan CEO	Chief Executive Officer	40	23-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,667,663	6,294,165 ( 35.63 %)	0	35.63 %

Name	Equities	%	Valuation
Choong-Chin Liew 9.367 %	1,666,667	9.367 %	988 334 $
Soo Lai 7.025 %	1,250,001	7.025 %	741 251 $
Chi Yuen Leong 6.557 %	1,166,673	6.557 %	691 837 $
Kim Hai Wong 5.904 %	1,050,539	5.904 %	622 970 $
Liong Tai Tan 5.855 %	1,041,706	5.855 %	617 732 $
Chan Chong Wong 5.797 %	1,031,427	5.797 %	611 636 $
Tham Kam 5.719 %	1,017,538	5.719 %	603 400 $
Tan Kuan Yew 3.340 %	594,243	3.340 %	352 386 $
Wei Foong Lim 2.836 %	504,603	2.836 %	299 230 $
Wei Li Leong 2.247 %	399,807	2.247 %	237 086 $

BioNexus Gene Lab Corp.

Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi

59200, Kuala Lumpur

+60 1 307 241 6898

http://www.bionexusgenelab.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIONEXUS GENE LAB CORP.	+9.43%	10.3M
MODERNA, INC.	+28.66%	49.18B
IQVIA HOLDINGS INC.	+0.96%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.38%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.60%	18.71B
BIO-TECHNE CORPORATION	+8.07%	13.26B
MEDPACE HOLDINGS, INC.	+32.17%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.42%	11.99B

Other Biotechnology & Medical Research